We’re still figuring out the side effects of GLP-1 weight-loss drugs
AI-rewritten: This is a summary of an article from MIT Technology Review, rewritten by AI (Qwen, running locally) to make it easier to read. The facts come from the original article – read it for the full story.
Research presented at an aging meeting in Boston suggests that overweight and diabetic people taking GLP-1 weight-loss drugs have a biological age two to three years younger than those on a placebo. Eli Lilly and Novo Nordisk, the companies that make these drugs, provided these findings. While approved for diabetes, kidney disease, and obesity, these medications are also being investigated for substance-use disorders, neurodegenerative disease, and cancer. A recent Gallup poll indicates 11% of Americans currently take a GLP-1 drug for weight loss, up from 3% in 2024, with 15% having used one at some point.